Objectives-E2 accelerates reendothelialization through estrogen receptor ␣ (ER␣), and we now aimed at defining the precise local and systemic cellular actors of this process. Methods and Results-The respective roles of endothelial and hematopoietic targets of E2 were investigated in a mouse carotid injury model, using confocal microscopy, to follow endothelium repair. Grafting ER␣ Ϫ/Ϫ mice with ER␣ ϩ/ϩ bone marrow (BM) was not sufficient to restore the accelerative effect of E2 on reendothelialization, demonstrating the necessary role of extrahematopoietic ER␣. Using an endothelial-specific inactivation of ER␣ (Cre-Lox system), we showed that endothelial ER␣ plays a pivotal role in this E2 action. Conversely, in ER␣ ϩ/ϩ grafted with ER␣ Ϫ/Ϫ BM, the E2 regenerative effect was abolished, demonstrating that ER␣-expressing hematopoietic cells are also needed. As eNOS expression in BM was required for this action, both endothelial progenitor cells and platelets could be the hematopoietic targets that participate to this beneficial E2 effect. Conclusions-We demonstrate that endothelial ER␣ plays a pivotal role in E2-mediated reendothelialization. However, endothelial targeting alone is not sufficient because the concomitant stimulation of a subpopulation of BM ER␣ is necessary. This cooperation should be taken into account in strategies aimed at optimizing in-stent reendothelialization. (Arterioscler Thromb Vasc Biol. 2009;29:1543-1550.)
A ngioplasty followed by stent implantation is a commonly used procedure to treat coronary or peripheral artery stenosis. The major complication of bare metal stent implantation is intrastent stenosis because of neointimal hyperplasia. Drug-eluting stents have emerged as a potential solution against restenosis, 1 but they also inhibit proliferation of endothelial cells. Late thrombosis has become a major concern, because delayed arterial healing, characterized by incomplete reendothelialization, constitutes an important underlying substrate for coagulation. 2, 3 Endothelium constitutes an antithrombogenic layer and limits neointima formation, and optimization of endothelial healing should be considered of primary importance. 4 Various treatment strategies to promote endothelial regrowth after arterial injury have been proposed. 5 Administration of angiogenic growth factors such as vascular endothelial growth factor 6 and fibroblast growth factor-2 (FGF-2) 7 increased endothelial healing in animal models. Endogenous mobilization or injection of ex vivo expanded endothelial progenitor cells (EPCs) was associated with enhanced reendothelialization. 8 Pharmacological agents including angiotensin-converting enzyme inhibition, 9 statins, 8, 10 and estrogens 11, 12 promote endothelial healing.
17␤-estradiol (E2), the main endogenous estrogen, exerts many vascular protective effects by increasing basal production of endothelial nitric oxide (NO), 13 accelerating reendothelialization 12, 14 or inhibiting neointima formation. 15 We previously demonstrated that E2 accelerates reendothelialization in a mouse model of perivascular carotid injury, through estrogen receptor (ER) ␣ but not ER␤. 11 E2 increases both migration and proliferation of cultured endothelial cells in vitro, 16 and these direct actions contribute to accelerate reendothelialization in vivo. 14 In addition, E2 exerts major effects on hematopoietic cells, as mobilization of EPCs, actions on inflammatory immune cells and platelets, that could contribute to endothelial repair. 15, 17 However, the respective contributions of E2 on endothelium and BM cells in this enhancing effect on the healing process have not been directly addressed. In the present work, we sought to determine whether endothelial ER␣, BM ER␣, or both participate to this beneficial effect of E2 on reendothelialization.
Methods

Animal Studies
Female mice were housed in groups of 6, kept in a temperaturecontrolled facility, on a 12-hour light-dark cycle, and fed normal laboratory chow diet. All procedures were performed in accordance with the guidelines established by the National Institute of Medical Research. In carotid injury experiments, mice were ovariectomized at 4 weeks of age and implanted or not with subcutaneous pellets releasing E2 (17␤-estradiol, 0.1 mg, 60-days release (ie, 80 g ⅐ kg Ϫ1 ⅐ d Ϫ1 , Innovative Research of America). E2 treatment was initiated 2 weeks before carotid injury and continued until the sacrifice ( Figure 1A ). ER␣ Ϫ/Ϫ mice 18 and eNOS Ϫ/Ϫ mice 19 were maintained in our animal facility. We systematically checked that ovariectomized and ER␣-deficient mice had an atrophied uterus (Ͻ20 mg) whereas those implanted with an E2-pellet had a significant increase in uterine weight, except for the ER␣ Ϫ/Ϫ mice (Table) .
Generation of Tie2Cre and LysMCre ER␣ KO Mice
Endothelium and macrophage/granulocyte-selective deletion of ER␣ was achieved by the loxP-Cre recombination system. Mice homozygous for floxed ER␣ in exon 2 (ER␣ flox/flox ) were crossed with transgenic mice expressing Cre recombinase under the control of the Tie2 or LysM promoter/enhancer, obtained from the Jackson Laboratory (Bar Harbor, Me). We obtained Tie2Cre ϩ/Ϫ ER␣ flox/flox mice which lack ER␣ in the endothelium (named Tie2Cre ϩ hereafter) and Tie2Cre Ϫ/Ϫ ER␣ flox/flox mice with intact ER␣ in the endothelium (named Tie2Cre Ϫ hereafter, used as control littermates). Ly-sMCre ϩ/Ϫ ER␣ flox/flox mice which lack ER␣ in macrophages/ granulocytes (named LysMCre ϩ herafter) and LysMCre Ϫ/Ϫ ER␣ flox/ flox mice with intact ER␣ (named LysMCreCre Ϫ hereafter, used as controlled littermates) have been specifically phenotyped, showing a specific inactivation of ER␣ in macrophages (unpublished data, Calippe B, Guery J.C.G., Gourdy P., 2009). Genotyping of the mice was performed for the Cre transgene and ER␣ by genomic PCR.
Mouse Carotid Injury
Mice were anesthetized by injection of ketamine (100 mg kg Ϫ1 ) and xylazine (10 mg kg Ϫ1 ) by intraperitoneal route. The perivascular carotid electric injury was performed as previously described. 11, 14 Briefly, surgery was carried out with a stereomicroscope (Nikon A, Mice were ovariectomized at 4 weeks of age and implanted or not with a pellet releasing E2. Carotid injury was performed at 6 weeks of age. Carotids were sampled 3 days after injury. The reendothelialized area (RE) was measured by confocal microscopy. B, Mice were irradiated and reconstituted with BM at 6 weeks of age. E2 treatment was initiated at 10 weeks of age. SMZ800) and the left common carotid artery was exposed via an anterior cervicotomy. The electric injury was applied to the distal part (4 mm precisely) of the common carotid artery with a bipolar microregulator. No formation of neointima was detectable after injury, probably as a consequence of the concomitant destruction of the medial smooth muscle, and the rapid and complete reendothelialization within 1 week.
For more detailed information, please see the supplemental materials (available online at http://atvb.ahajournals.org).
Results
ER␣ Expression in the Hematopoietic Compartment Alone Is Not Sufficient to Mediate E2 Reendothelialization
We previously demonstrated that ER␣ mediates the accelerative effect of E2 on reendothelialization. 11 Several studies strongly suggested that BM-derived cells as EPCs are involved in endothelial healing. 20 -22 To clarify whether BM cells are sufficient to mediate the entire effect of E2 on endothelial healing, we generated hematopoietic chimeric mice by grafting ER␣ ϩ/ϩ BM to ER␣ Ϫ/Ϫ mice. We verified by PCR the restoration of a normal expression of ER␣ in the hematopoietic compartment (data not shown).
We then measured the reendothelialized area by "en face" confocal microscopy. Whereas the accelerative effect of E2 was still observed in control irradiated mice as expected, it was completely abolished in the chimeric ER␣ ϩ/ϩ 3 ER␣ Ϫ/Ϫ mice (Pϭ0.45; Figure 2 ), demonstrating that ER␣-expressing hematopoietic cells are not sufficient to mediate this effect.
This result also suggests that a resident, extrahematopoietic, cellular target might play a pivotal role.
Generation of Tie2Cre ؉ Mice With Endothelial-Specific ER␣ Deletion
Among the potential local targets of E2, endothelial cells appeared to be natural candidates. Endothelium-specific inactivation of ER␣ was achieved by breeding floxed ER␣ mice with Tie2Cre transgenic mice, as Tie2 is expressed in endothelial cell-lineage. 23 We showed that the floxed and deleted ER␣ gene were still detected in isolated aorta from Tie2Cre ϩ mice while scraping endothelium strongly abrogated expression of the deleted allele, demonstrating that the Tie2Cre transgene leads to specific inactivation of ER␣ in endothelial cells ( Figure 3B ).
However, Tie2Cre ϩ mice also present an inactivation of ER␣ in hematopoietic cells. 24 Indeed, quantitative RT-PCR showed that expression of ER␣ in BM, spleen, and blood was dramatically reduced in Tie2Cre ϩ mice ( Figure 3C ), confirming deletion of ER␣ in hematopoietic cell-lineage. To restrict the ablation of ER␣ in endothelial cells, Tie2Cre ϩ mice were irradiated and then grafted with BM from wild-type mice. As expected, quantitative RT-PCR analysis showed that ER␣ expression in BM, spleen, and blood from these chimeric mice was restored by 100% ( Figure 3C ).
Endothelial Expression of ER␣ Is Necessary for the Accelerative Effect of E2 on Reendothelialization
Three days after injury, the lengths of the reendothelialized areas were 424Ϯ14 m and 448Ϯ30 m in untreated and E2-treated Tie2Cre ϩ animals, respectively. In contrast, in control littermates, the lengths of the reendothelialized areas were 455Ϯ40 m and 681Ϯ52 m in untreated and E2treated Tie2Cre Ϫ animals, respectively ( Figure 4A and 4B) . Thus, the beneficial effect of E2 on reendothelialization was To reverse the deletion of ER␣ also present in hematopoietic cells from Tie2Cre ϩ mice, we studied reendothelialization in Tie2Cre ϩ mice grafted with wild-type BM. Tie2Cre Ϫ grafted with wild-type BM were used as controls. The E2 effect on reendothelialization was conserved in Tie2Cre Ϫ mice grafted with wild-type BM, whereas it was abolished in Tie2Cre ϩ mice grafted with wild-type BM ( Figure 4C ). Thus, ER␣ expression in endothelial cells is absolutely required to mediate the accelerative effect of E2 on reendothelialization.
BM ER␣ Is Also Required for the E2 Effect on Reendothelialization
Although the present data clearly indicate that activation of endothelial ER␣ is necessary for the accelerative effect of E2, previous experimental studies suggested that BM-derived cells, especially EPCs, could be key actors in this action. 15, 25 To determine whether the accelerative effect of E2 could be obtained by activating only extrahematopoietic ER␣ (ie, the endothelial ER␣) we grafted ER␣ Ϫ/Ϫ BM to irradiated ER␣ ϩ/ϩ mice (chimeric mice deficient in hematopoietic ER␣). Surprisingly, the accelerative effect of E2 was abolished in these chimeric mice (Pϭ0.46; Figure 5A ). Interestingly, the E2 effect was also abolished when eNOS was absent in BM-derived cells, whereas it was still present in eNOS Ϫ/Ϫ mice grafted with wild-type BM ( Figure 5A) . Altogether, the presence of both ER␣ and eNOS in BM cells is mandatory for the accelerative effect of E2 on reendothelialization.
To further determine the effects of these hematopoietic cells, we established a BM transplantation model in which BM cells could be identified by GFP expression ( Figure 5B through 5F). Three days after carotid injury, we observed that only a few GFP-positive cells were present at the level of the endothelium (Figure 5C and 5F) with no difference in density between untreated and E2-treated mice (4.1%Ϯ 0.3 and 3.7%Ϯ 0.4, respectively; Figure 5G ). None of these cells were observed in the intimal layer 30 days after injury (data not shown). No BM-derived GFP cells were found in the medial layer 3 days after injury ( Figure 5D and 5F), whereas they were very abundant in the adventitia ( Figure 5E and 5F) , an infiltration that persisted at day 30 postinjury (data not shown).
Macrophages and Granulocytes Expression of ER␣ Is Dispensable for the Accelerative Effect of E2 on Reendothelialization
Because the GFP-positive cells in the adventitia were thought to be mainly macrophages, we sought to explore their role using cell-specific inactivation of ER␣, by breeding LysMCre mice with floxed ER␣ (LysM is expressed by macrophages and neutrophils).
The accelerative effect of E2 on reendothelialization was then investigated. Three days after injury, the lengths of the reendothelialized areas were increased by E2 in both Ly-sMCre ϩ and LysMCre Ϫ mice (431Ϯ19 m and 556Ϯ24 m in untreated and E2 treated LysMCre ϩ [meansϮSEM], respectively). In control littermates, the lengths of the reendothelialized areas were 456Ϯ19 m and 579Ϯ23 m in untreated and E2-treated LysMCre Ϫ (meansϮSEM), respectively. Thus, macrophages and granulocyte ER␣ expression is dispensable for E2-mediated reendothelialization. These data indicated that cells from myeloid lineage do not significantly contribute to the E2 effect on reendothelialization. 
Discussion
We previously reported that ER␣ is the key molecular target of E2-mediated reendothelialization. 11 Despite many studies aimed at understanding the cellular targets involved in reendothelialization, the precise role of the local and systemic actors of this process has never been clearly established.
In the last decade, literature focused on the potential role of BM-derived progenitors/supporting cells not only in angiogenesis 26 but also in reendothelialization. 27 We first sought to investigate whether BM-derived cells were sufficient to support the accelerative effect of E2 on reendothelialization. However, E2 failed to accelerate reendothelialization in ER␣ Ϫ/Ϫ mice grafted with ER␣ ϩ/ϩ BM (still deficient in extrahematopoietic ER␣). This result indicates that E2 action restricted to BM derived cells is not sufficient to mediate the effect on endothelial healing. The 2 major extra-BM candidates are resident endothelial cells and smooth muscle cells that constitute the main and almost unique cell type of the intima and media, respectively. To our knowledge, implication of smooth muscle cells in the reendothelialization process in vivo has not yet been directly investigated. However, when we recently compared the endovascular (where smooth muscle cells are preserved) and the perivascular model used in the present work (where complete decellularization of both endothelial and smooth muscle cells is achieved), 14 we found that both basal and E2-stimulated velocity of reendothelialization were similar in the 2 models. This result strongly indicates that the underlying smooth muscle cells play a limited role, if any, in the accelerative effect of E2 on reendothelialization.
Thus, we decided to explore directly the action of E2 on endothelial ER␣, using Tie2Cre ϩ mice. We found that the beneficial effect of E2 was completely abolished in this model. Furthermore, the lack of accelerative action of E2 also persisted in Tie2Cre ϩ grafted with the wild-type BM, despite the restoration of ER␣ expression in BM-derived cells. Indeed, inactivation of ER␣ using the Cre-Lox system under the control of the Tie2 promoter concomitantly inactivates expression of ER␣ in the endothelium and in the hematopoietic compartment, as previously described 24 and as confirmed here (see Figure 3 ). Endothelial ER␣ is therefore absolutely required for the accelerative effect of E2 on reendothelialization, an observation reminiscent of the stimulatory action of E2 on the migration and proliferation of endothelial cells in vitro. 16 However, we found that this E2 action on endothelial ER␣ is not sufficient in vivo and that other cellular targets of E2 are mandatory. Indeed, inactivation of ER␣ in the hematopoietic compartment completely abolished the E2 effect in this model. Thus, ER␣ expression in endothelial cells is absolutely necessary to mediate the E2 effect on reendothelialization, but not sufficient, because it also requires involvement of BM-derived cells.
Accordingly, previous studies suggested that several BMderived cells, such as EPCs, macrophages, and platelets, are potential candidates to mediate this action. Indeed, intravenous infusion of EPCs accelerated reendothelialization, 25 and E2 increased the number of circulating EPCs as well as the incorporation of BM-derived cells in the reendothelialized area. 15, 28 However, most of these experiments showed a correlation between EPC increase and acceleration of reendothelialization rather than a causative relationship. 29 To further characterize the relationship between BM-derived cells and the regenerating endothelial cell monolayer, we grafted GFP-BM to wild-type mice and found that only a few GFP-positive cells (3% to 4% of intima cells) were present at the level of the regenerated endothelial cell monolayer, irrespective of the E2 treatment. Noteworthy, they were no longer detectable 30 days postinjury, indicating that these cells did not incorporate into the regenerated endothelium. If EPCs are defined as cells differentiating into endothelial cells and incorporating into the new vascular network, 26, 30 the absence of GFP-positive cells in healed carotid artery (30 days post injury) suggests no direct contribution of "true" EPCs. At least some initially called EPCs appear to be BM-derived cells with monocyte characteristics. Thus, if these intimal GFP-positive cells play a role in the E2 action and although their density were not influenced by E2 at day 3, they could act essentially in a paracrine manner to promote reendothelialization as reported for angiogenesis. 26 To make the story even more complex, true endothelial progenitors with high proliferative potential, detected in the vessel wall itself, might not be restricted to BM but could derived directly from the vessel wall. 31, 32 Monocytes/macrophages are clearly direct targets for E2 33 and were previously reported to modulate angiogenesis. Interestingly, they could thereby also be a candidate for endothelial regeneration, although macrophage colonystimulating factor had no effect on reendothelialization. 34 Moreover, Geissman et al demonstrated that a subset of resident monocytes patrol and are rapidly recruited in inflammatory sites where they differentiated into macrophages. 35 Because this population is patrolling the surface of the endothelium through long-range crawling, it could therefore be involved in the modulation of reendothelialization. In consequent, we used LysMCre ER␣ flox/flox mice to clarify the potential role of myeloid cell lineage in E2-mediated reendothelialization. In double mutant mice, harboring LysMCre and loxP-flanked target genes, Förster et al showed a deletion efficiency of 83% to 98% and near 100% in mature macrophages and granulocytes, respectively, whereas partial deletion (16%) was detected in dendritic cells. 36 Our results indicate that neither macrophages nor neutrophils contribute to the accelerative effect of E2 on reendothelialization.
Platelets are also abundant in the deendothelialized area 37 and release factors that can directly 38 or indirectly 39 contribute to the acceleration of reendothelialization. In this respect, it is noteworthy that E2 was reported to modulate platelet physiology. 40, 41 Finally, a yet unrecognized circulating factor secreted by E2-stimulated hematopoietic cells could have contributed to its effect on reendothelialization.
We reported here that eNOS expression in BM is important to mediate the E2 effect on reendothelialization, whereas the E2 effect persisted in chimeric eNOS Ϫ/Ϫ grafted with wildtype BM, although lesser in magnitude. Both EPCs 42 and platelets 43 were reported to express eNOS. Moreover, we have previously shown that BM-derived FGF-2 was absolutely required in the accelerative effect of E2 in reendothelialization, whereas in nonhematopoietic cells FGF-2 was dispensable, 29 showing that both FGF-2 and eNOS are key molecular actors of the E2 action at the level of the BM.
Thus, the identification of the specific BM-derived cell populations responsible for the reendothelialization process remains difficult because it will require the development of the cell-specific inactivation of ER␣ in these BM-derived populations, tools that are not yet available in our laboratory.
In summary, the present study demonstrates that expression of ER␣ in both BM compartment and endothelial cells is required to mediate the accelerative effect of E2 on reendothelialization. This should be taken into account in designing strategies aimed at promoting postangioplasty reendothelialization. For instance, E2-eluting stents could not be sufficient to efficiently accelerate reendothelialization. Accordingly, in the only in-man randomized trial (ETHOS I trial), E2-eluting stents did not show any benefit for treatment of coronary lesions when compared to bare metal stents. 44 Recognizing the BM-derived actors that contribute to promote reendothelialization represents an important challenge to optimize in-stent vascular healing.
